Fake news? Narcan maker forced to refute licensing deal after wire service apparently duped by false announcement

Max Gelman

Senior Editor

While most everyone was in a TGIF mood and getting ready for the weekend, Opiant Pharmaceuticals spent last Friday afternoon fending off a fake press …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Fake news? Narcan maker forced to refute licensing deal after wire service apparently duped by false announcement

Max Gelman

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Some FDA medical device staff reinstated just days after receiving pink slips

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

Alcon tried to sink Aurion's IPO in 'Valentine's Day massacre,' new lawsuits say

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

How AI can address ongoing challenges in the life sciences industry

Fake news? Nar­can mak­er forced to re­fute li­cens­ing deal af­ter wire ser­vice ap­par­ent­ly duped by false an­nounce­ment

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Fake news? Narcan maker forced to refute licensing deal after wire service apparently duped by false announcement